Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial.
作者信息
De Angelis Claudia, Ignatiadis Michail, Piccart-Gebhart Martine
机构信息
Medical Oncology Department, Academic Trials Promoting Team, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
出版信息
Ann Transl Med. 2020 Nov;8(21):1338. doi: 10.21037/atm-20-3216.
Abstract
摘要
相似文献
1
Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial.细胞周期蛋白依赖性激酶4和6抑制剂（CDK4/6i）与化疗治疗管腔B型早期乳腺癌的比较：CORALLEEN试验的经验教训
Ann Transl Med. 2020 Nov;8(21):1338. doi: 10.21037/atm-20-3216.
2
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.来曲唑联合瑞波西利对比化疗用于激素受体阳性、HER2 阴性、腔面 B 型乳腺癌的绝经后女性（CORALLEEN）：一项开放标签、多中心、随机、2 期临床试验。
Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11.
3
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.Elacestrant（RAD1901）在多种对 CDK4/6 抑制剂耐药的 ER+ 乳腺癌模型中表现出抗肿瘤活性。
Breast Cancer Res. 2019 Dec 18;21(1):146. doi: 10.1186/s13058-019-1230-0.
4
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.细胞周期蛋白依赖性激酶4和6抑制剂停用后乳腺癌疾病进展迅速
J Cancer. 2017 Jul 5;8(11):2004-2009. doi: 10.7150/jca.18196. eCollection 2017.
5
Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.克服激素受体阳性晚期乳腺癌中的内分泌抵抗——CDK4/6抑制剂的新作用
Int J Cancer Clin Res. 2015;2(4). doi: 10.23937/2378-3419/2/4/1029. Epub 2015 Oct 14.
6
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.在癌症治疗中抑制 CDK：当前证据和未来方向。
Target Oncol. 2018 Feb;13(1):21-38. doi: 10.1007/s11523-017-0541-2.
7
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.CDK4/6 抑制剂拓展乳腺癌治疗选择：哌柏西利、瑞博西利和阿贝西利。
BioDrugs. 2019 Apr;33(2):125-135. doi: 10.1007/s40259-019-00337-6.
8
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.FAT1 肿瘤抑制因子丢失通过 Hippo 通路促进 CDK4/6 抑制剂耐药性。
Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006.
9
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.血浆衍生外泌体中 TK1 和 CDK9 的过表达与转移性乳腺癌患者对 CDK4/6 抑制剂的临床耐药相关。
Breast Cancer Res Treat. 2019 Nov;178(1):57-62. doi: 10.1007/s10549-019-05365-y. Epub 2019 Jul 26.
10
Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.细胞周期蛋白依赖性激酶 4/6 抑制剂在激素受体阳性早期乳腺癌中的应用：初步结果和正在进行的研究。
Breast Cancer. 2018 Sep;25(5):506-516. doi: 10.1007/s12282-018-0864-6. Epub 2018 Apr 26.
引用本文的文献
1
FASN inhibition as a potential treatment for endocrine-resistant breast cancer.脂肪酸合酶抑制作为一种潜在的内分泌抵抗型乳腺癌治疗方法。
Breast Cancer Res Treat. 2021 Jun;187(2):375-386. doi: 10.1007/s10549-021-06231-6. Epub 2021 Apr 24.
本文引用的文献
1
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.来曲唑联合瑞波西利对比化疗用于激素受体阳性、HER2 阴性、腔面 B 型乳腺癌的绝经后女性（CORALLEEN）：一项开放标签、多中心、随机、2 期临床试验。
Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11.
2
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.瑞博西利联合氟维司群治疗晚期乳腺癌的总生存期。
N Engl J Med. 2020 Feb 6;382(6):514-524. doi: 10.1056/NEJMoa1911149. Epub 2019 Dec 11.
3
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.帕博西尼联合戈舍瑞林与卡培他滨用于激素受体阳性、HER2 阴性转移性乳腺癌绝经前妇女（KCSG-BR15-10）：一项多中心、开放标签、随机、2 期临床试验。
Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24.
4
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR/HER2 Breast Cancer.在 HR/HER2 乳腺癌的 neoMONARCH Ⅱ期新辅助研究中，阿贝西利联合来曲唑具有强大的细胞周期抑制作用，并上调免疫应答。
Clin Cancer Res. 2020 Feb 1;26(3):566-580. doi: 10.1158/1078-0432.CCR-19-1425. Epub 2019 Oct 15.
5
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.阿贝西利联合氟维司群治疗激素受体阳性、HER2 阴性乳腺癌的疗效：内分泌治疗进展后总生存的影响——MONARCH 2 随机临床试验
JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782.
6
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.绝经后激素受体阳性、HER2 阴性转移性乳腺癌患者的内分泌治疗与化疗：系统评价和网络荟萃分析。
Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4.
7
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.瑞博西利联合内分泌治疗乳腺癌的总生存。
N Engl J Med. 2019 Jul 25;381(4):307-316. doi: 10.1056/NEJMoa1903765. Epub 2019 Jun 4.
8
Genomic characterization of metastatic breast cancers.转移性乳腺癌的基因组特征分析。
Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22.
9
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.异常的 FGFR 信号转导介导 ER+乳腺癌对 CDK4/6 抑制剂的耐药性。
Nat Commun. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2.
10
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.细胞周期蛋白 E1 表达与帕博西尼在既往治疗的激素受体阳性转移性乳腺癌中的疗效。
J Clin Oncol. 2019 May 10;37(14):1169-1178. doi: 10.1200/JCO.18.00925. Epub 2019 Feb 26.
Zotero 插件